Indomethacin

證據等級: L5

預測適應症: 10 個

Indomethacin: From Inflammatory Disease to Juvenile Idiopathic Arthritis

One-Sentence Summary

Indomethacin is a potent COX-1/COX-2 inhibitor (NSAID) with decades of clinical use in adult inflammatory conditions including arthritis, gout, and ankylosing spondylitis. The TxGNN model identifies Juvenile Idiopathic Arthritis (JIA) as the highest-evidence predicted indication among 10 candidates, with 0 registered clinical trials but 20 supporting publications — including a double-blind RCT directly comparing indomethacin in juvenile chronic arthritis, giving it an L2 evidence rating and an actionable “Proceed with Guardrails” recommendation.

Quick Overview

Item	Content
Original Indication	Not recorded in current dataset
Predicted New Indication	Juvenile Idiopathic Arthritis
TxGNN Prediction Score	99.84%
Evidence Level	L2
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Note: This is a multi-indication analysis (10 predictions total). Ranks #1–7 are rare genetic skeletal syndromes with no clinical or preclinical evidence (all L5/Hold). Juvenile Idiopathic Arthritis (rank #8) is the highest-evidence actionable indication and is the primary focus of this report.

Why is This Prediction Reasonable?

Indomethacin inhibits both COX-1 and COX-2 enzymes, blocking the conversion of arachidonic acid into prostaglandins. The resulting reduction in prostaglandin E2 (PGE2) suppresses vasodilation, leukocyte recruitment, and the amplification of pro-inflammatory cytokine signals — producing both analgesic and anti-inflammatory effects. Detailed MOA data from DrugBank is currently unavailable (Data Gap DG002), but the pharmacological mechanism is well-established in the literature.

Juvenile Idiopathic Arthritis encompasses several subtypes of chronic inflammatory arthritis in children under 16, characterised by persistent joint inflammation, morning stiffness, and risk of progressive joint destruction. Its pathophysiology is driven by dysregulated immune activation involving IL-1β, IL-6, and TNF-α — all of which rely on prostaglandins as downstream amplifiers of the inflammatory cascade. NSAIDs targeting this prostaglandin axis are therefore first-line symptomatic agents in JIA management.

Historically, indomethacin was among the earliest NSAIDs used in juvenile chronic arthritis (JCA, the predecessor classification to JIA). A 1978 double-blind crossover trial in 30 children confirmed indomethacin as both a safe and effective anti-inflammatory and analgesic in JCA — and found it to be the preferred agent over ketoprofen. Multiple clinical reviews from the 1980s–1990s also list indomethacin alongside aspirin as the established NSAID backbone for systemic JIA fever control. The TxGNN knowledge graph prediction almost certainly reflects this mechanistic and historical connection captured as high-density edges in the drug–disease network.

Clinical Trial Evidence

Currently no related clinical trials are registered for Indomethacin in Juvenile Idiopathic Arthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
362571	1978	RCT (double-blind crossover)	South African Medical Journal	Indomethacin vs ketoprofen in 30 children with JCA — both effective; indomethacin emerged as the preferred drug
28418334	2017	Review	Balkan Medical Journal	Comprehensive overview of JIA subtypes, clinical features, and current treatment modalities
22573189	2012	Review	Swiss Medical Weekly	Systemic-onset JIA (Still’s disease): orphan disease with chronic course, unique response profile to conventional immunosuppressants
1379157	1992	Clinical Review	Drugs	NSAIDs — including indomethacin — described as the foundation of pharmacotherapy for juvenile rheumatoid arthritis
8422565	1993	Review	British Journal of Rheumatology	NSAIDs in paediatric rheumatic disease; indomethacin specifically noted for systemic JCA fever control, though more toxic than alternatives
28086918	2017	Observational	Pediatric Rheumatology Online Journal	Atypical monoarthritis presentation in oligoarticular JIA; clinical management context
7417361	1980	Comparative Study	Arthritis and Rheumatism	JRA cohort comparison (USSR vs USA); documents therapeutic practices and NSAID reliance
1884567	1991	Clinical Review	Clinical Pharmacokinetics	Pharmacokinetics of NSAIDs including indomethacin in juvenile arthritis; dosing and clearance considerations
5632159	1967	Clinical Study	Arzneimittel-Forschung	Long-term indomethacin therapy in juvenile rheumatoid arthritis and Still’s disease — early efficacy data
23312448	2013	Basic Research	Cytotherapy	Mesenchymal stromal cells in systemic JIA suppress immune responses; mechanistic context for combination approaches

India Market Information

Indomethacin has no recorded product registrations in the current dataset (0 licences on file). No approved indication text is available.

Safety Considerations

Drug Interactions (252 interactions on record; key interactions listed below):

Interacting Drug	Level	Clinical Relevance
Acetylsalicylic acid	Moderate	Concurrent NSAID use significantly increases GI bleeding and ulceration risk
Hydrocortisone	Moderate	Corticosteroid + NSAID combination raises GI ulceration risk; monitor closely
Dexamethasone	Moderate	As above; particularly relevant in JIA patients on steroid bridges
Betamethasone	Moderate	As above
Budesonide	Moderate	As above
Triamcinolone	Moderate	As above
Metformin	Moderate	NSAIDs may reduce renal clearance of metformin via prostaglandin-mediated renal effects
Mesalazine	Moderate	Risk of additive renal toxicity; monitor renal function
Balsalazide	Moderate	Monitor renal function with concurrent use
Glimepiride	Moderate	NSAIDs may potentiate hypoglycaemic effect of sulphonylureas
Famotidine	Minor	H2 blockers often co-prescribed for GI mucosal protection with NSAIDs
Ranitidine	Minor	As above
Cimetidine	Minor	As above

Complete warnings and contraindications are not available in the current dataset (Data Gap DG001). Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Indomethacin has documented historical clinical use in juvenile chronic arthritis backed by a double-blind RCT and multiple clinical reviews spanning five decades. The COX inhibition → PGE2 reduction → joint inflammation control mechanism directly maps onto JIA pathophysiology. However, current paediatric rheumatology guidelines have shifted towards naproxen, ibuprofen, and diclofenac as preferred first-line NSAIDs due to indomethacin’s comparatively higher GI and CNS toxicity burden; biologics (tocilizumab, etanercept) are now standard for refractory disease.

To proceed, the following is needed:

Safety data (Blocking): Obtain CDSCO/TFDA package insert to fill DG001 — warnings and contraindications are currently unknown
MOA documentation (High): Query DrugBank API for complete mechanism of action (DG002) to strengthen mechanistic rationale
Comparative benefit–risk review: Head-to-head evidence against currently preferred NSAIDs in JIA (naproxen, ibuprofen, diclofenac) to establish whether indomethacin offers any advantage in specific JIA subtypes (e.g., systemic JIA fever)
Paediatric dosing review: Confirm age-appropriate dosing, weight-based regimens, and paediatric pharmacokinetic data specific to JIA
Regulatory pathway assessment: Evaluate feasibility of India registration for the JIA indication given current market status (not marketed, 0 registrations)
Subtype stratification: Clarify which JIA subtypes (systemic, oligoarticular, polyarticular RF+/RF−) may benefit most, given the mechanistic literature is heterogeneous
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.